No profile data available.
Mirum Pharmaceuticals, Inc. (MIRM) is a healthcare company in the hepatic treatment pharmaceuticals industry, based in Foster City, United States, with about 433 full-time employees.
It reported revenue of $521.31 million for fiscal year 2025, up 54.7% from fiscal year 2024, and net income of -$23.36 million. United States was its largest region in fiscal year 2025, with 77% of revenue. Its market capitalization was $5.58 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Mirum Pharmaceuticals reported $521.31 million in revenue for fiscal year 2025, up 54.7% from $336.89 million in fiscal year 2024.
United States: 77% of revenue by region in fiscal year 2025, followed by Rest of the World (23%).
$5.58 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (hepatic treatment pharmaceuticals) include Madrigal Pharmaceuticals, Inc. (MDGL), Arrowhead Pharmaceuticals, Inc. (ARWR), Inventiva S.a. (IVA), Wave Life Sciences Ltd. (WVE).